<DOC>
	<DOCNO>NCT02044276</DOCNO>
	<brief_summary>The primary objective study demonstrate non-inferiority lipegfilgrastim pegfilgrastim duration severe neutropenia first cycle chemotherapy .</brief_summary>
	<brief_title>A comparatiVe Study Efficacy Safety Lipegfilgrastim Comparison Pegfilgrastim Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas hIgh Risk R-CHOP-21-inDuced Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>1 . Signed dated Independent Ethics Committee ( IEC ) approve write informed consent 2 . Age ≥65 year ≤85 year 3 . Histological documentation aggressive B cell NHL 4 . Planned receive systemic anticancer therapy least 6 cycle RCHOP21 , accord local standard 5 . ECOG score ≤2 6 . Life expectancy least 3 month 7 . Adequate bone marrow , renal hepatic function within 14 day start chemotherapy 8 . The patient capable understanding comply parameter outline protocol 9 . Women childbearing potential ( surgically sterile 2 year postmenopausal ) must use medically accept method contraception must agree continue use method duration treatment 30 day discontinuation study drug . 10 . The patient , man , surgically sterile , , capable produce offspring , currently use approve method birth control agree continue use method duration treatment ( 90 day take last dose study Other Criteria apply , please contact investigator information 1 . Participation clinical study within 30 day randomization 2 . Any chemotherapy within last 3 month start chemotherapy . A prephase reduce tumor burden prior start RCHOP allow . 3 . The patient pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) 4 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start chemotherapy . 5 . Active cardiac disease 6 . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start chemotherapy . 7 . Ongoing infection , know history human immunodeficiency virus ( HIV ) infection , tuberculosis , chronic hepatitis B C. 8 . Patients evidence history bleed diathesis . 9 . Nonhealing wound , ulcer bone fracture . 10 . Renal failure require hemo peritoneal dialysis . 11 . Any condition may interfere patient 's participation study evaluation study result . 12 . Known hypersensitivity study drug , study drug class , excipients formulation . 13 . Any illness medical condition unstable could jeopardize safety patient his/her compliance study . 14 . Treatment lithium screening plan study . Other Criteria apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>NHL</keyword>
	<keyword>Non-Hodgkin lymphoma</keyword>
	<keyword>R-CHOP-21</keyword>
</DOC>